WASHINGTON, D.C. — In a strategic move aimed at fortifying the nation’s epidemiological infrastructure, METAvivor, a leading non-profit organization dedicated to metastatic breast cancer (MBC) research and awareness, has formally petitioned the United States Congress to ensure robust funding for the nation’s primary cancer registries. As the federal government begins its long-range fiscal planning, METAvivor’s leadership is looking toward the 2027 appropriations cycle to secure the future of the Centers for Disease Control and Prevention’s (CDC) National Program of Cancer Registries (NPCR) and the National Cancer Institute’s (NCI) Surveillance, Epidemiology, and End Results (SEER) program.
The advocacy effort, underscored by a detailed letter to the Senate Appropriations Subcommittee on Labor, Health and Human Services, Education, and Related Agencies, highlights a critical reality: without precise, real-time data, the "War on Cancer" is being fought with an incomplete map. For the metastatic community, where disease progression and recurrence are the primary concerns, the modernization and maintenance of these registries are not merely administrative tasks—they are matters of life and death.
Main Facts: The Intersection of Data and Survival
At the heart of METAvivor’s advocacy is the recognition that cancer registries are the backbone of public health strategy. These databases collect information on cancer incidence, prevalence, and survival, providing the raw material that researchers use to identify trends, allocate resources, and develop new therapeutic interventions.
The Role of NPCR and SEER
The American cancer surveillance system relies on two primary pillars:
- The CDC’s National Program of Cancer Registries (NPCR): Established in 1992, the NPCR supports central cancer registries in 45 states, the District of Columbia, Puerto Rico, and the U.S. Pacific Island Jurisdictions. It covers approximately 96% of the U.S. population.
- The NCI’s Surveillance, Epidemiology, and End Results (SEER) Program: Since 1973, SEER has provided highly detailed data from specific geographic regions, covering about 48% of the population. SEER is often considered the "gold standard" for cancer statistics due to its longitudinal depth.
The Metastatic Gap
METAvivor’s specific interest lies in a historical deficiency within these registries: the undercounting of metastatic recurrence. Traditionally, registries have been highly effective at capturing "stage at initial diagnosis." However, if a patient is diagnosed with Stage II breast cancer and the disease later metastasizes to Stage IV, that transition is frequently not captured in national databases. This leads to a significant underestimation of the number of people living with metastatic disease, which in turn results in disproportionately low research funding and inadequate healthcare planning.
By advocating for 2027 funding levels, METAvivor is pushing for the technical upgrades necessary to track patients throughout their entire "cancer journey," ensuring that every stage of the disease is recorded.
Chronology: A Decades-Long Battle for Better Data
The path toward comprehensive cancer tracking in the United States has been a slow evolution, marked by legislative milestones and technological shifts.
- 1971: President Richard Nixon signs the National Cancer Act, effectively launching the "War on Cancer." This creates the mandate for the NCI to collect and disseminate data, leading to the birth of the SEER program.
- 1973: The SEER program begins collecting data in select states, providing the first systematic look at cancer survival rates in the U.S.
- 1992: Recognizing that SEER did not cover the entire country, Congress passes the Cancer Registries Amendment Act, establishing the NPCR under the CDC to fill the gaps in state-level data collection.
- 2010s: The rise of Electronic Health Records (EHRs) presents a double-edged sword. While digital data offers the potential for real-time tracking, fragmented systems make it difficult for registries to pull data automatically.
- 2017: A landmark study published in Cancer Epidemiology, Biomarkers & Prevention estimates that the number of women living with metastatic breast cancer in the U.S. is much higher than previously thought, highlighting the "missing" data in registries.
- 2020-2023: The COVID-19 pandemic disrupts data collection, leading to delays in reporting and a renewed realization that the public health data infrastructure requires significant federal investment to remain resilient.
- Present Day: METAvivor and other advocacy groups initiate a "pre-emptive strike" on the 2027 budget cycle, recognizing that the legislative process for health appropriations requires years of consistent pressure to ensure that funding keeps pace with inflation and technological needs.
Supporting Data: Why Every Dollar Matters
The call for increased funding is supported by staggering statistics regarding the burden of cancer and the cost-efficiency of data-driven research.
Prevalence and Mortality
According to the American Cancer Society, over 2 million new cancer cases are expected to be diagnosed in the U.S. in 2024. Breast cancer remains the most common cancer among women, and metastatic breast cancer accounts for nearly all of the roughly 42,000 deaths from the disease each year.
The Funding-to-Outcome Ratio
Research indicates that every dollar spent on cancer surveillance yields a high return on investment by preventing "blind" spending. For example, by identifying clusters of high mortality in specific zip codes, the CDC can deploy targeted screening programs, reducing late-stage diagnoses and saving the healthcare system billions in treatment costs.
The Modernization Need
Currently, many state registries still rely on manual data entry or outdated reporting formats. Experts estimate that a full modernization of the NPCR and SEER programs—integrating artificial intelligence to parse pathology reports and clinical notes—would require a sustained increase in annual funding. METAvivor argues that the 2027 budget must account for this digital transformation to prevent the U.S. from falling behind in precision medicine.
Official Responses and Stakeholder Perspectives
The advocacy letter sent by METAvivor to the Senate Appropriations Subcommittee has sparked a broader conversation among policymakers and health officials.
The Advocacy Voice
In their communication, METAvivor emphasized that "Consistent and strong support for these registries is essential in our fight against cancer." The organization argues that patients who are currently living with metastatic disease are often "invisible" in the data, which affects their access to clinical trials and specialized care. By securing funding for 2027, METAvivor seeks to ensure that the "Cancer Moonshot" goals set by the White House are backed by a solid data foundation.
Congressional Outlook
Members of the Senate Appropriations Subcommittee have historically shown bipartisan support for cancer research. However, the fiscal environment is increasingly constrained. Lawmakers are balancing the need for health innovation with calls for overall spending caps. The response from the subcommittee usually involves a delicate negotiation between the CDC’s operational needs and the NCI’s research priorities.
The Scientific Community
Leaders within the NCI and CDC have long advocated for "registry modernization." In previous testimony, officials have noted that the goal is to move from "passive surveillance" (waiting for reports to come in) to "active surveillance" (pulling data directly from hospital systems). This shift requires not just hardware, but a highly trained workforce of registrars and data scientists—positions that depend entirely on federal funding stability.
Implications: The Long-Term Impact of Fiscal Neglect vs. Investment
The decisions made regarding 2027 funding levels will have ripples that last for decades. The implications of this legislative push are three-fold:
1. Precision Medicine and Clinical Trials
If registries are adequately funded and modernized, they can serve as a matchmaking tool for clinical trials. Currently, finding patients for specific Stage IV trials is a manual and arduous process. A robust SEER/NPCR system could identify eligible patients in real-time, accelerating the development of life-saving drugs.
2. Health Equity and Disparity Reduction
Data registries are the only way to accurately track health disparities among different racial, ethnic, and socioeconomic groups. Without strong funding, data from underserved rural or inner-city populations is often the first to suffer from under-reporting. METAvivor’s push ensures that the fight against cancer remains inclusive and that no demographic is left out of the national statistics.
3. The Future of AI in Oncology
The next frontier of cancer care involves Artificial Intelligence (AI) and Machine Learning (ML). These technologies require massive datasets to "learn" how to predict patient outcomes or identify which treatments will work for which genetic profiles. If the 2027 budget fails to support the data infrastructure, the U.S. risks stifling the growth of the domestic biotech industry and delaying the arrival of AI-driven cures.
Conclusion
METAvivor’s proactive stance on the 2027 federal budget serves as a reminder that the battle against cancer is fought as much in the halls of Congress as it is in the laboratory. By championing the NPCR and SEER programs, the organization is advocating for the "eyes and ears" of the medical community.
As the Senate Appropriations Subcommittee begins the arduous task of setting funding levels, the message from the metastatic community is clear: you cannot cure what you do not count. The strength of America’s cancer registries in 2027 will determine the speed of discovery and the quality of survival for millions of Americans in the decade to follow.
For the patients represented by METAvivor, these registries are more than just numbers; they are the evidence of their existence and the blueprint for their future.
About the Author
